1.646.889.1200|info@lifescipublicrelations.com

This Biotech Stock With A 221% Gain In 2019 Is Ready For ‘Prime Time’

//This Biotech Stock With A 221% Gain In 2019 Is Ready For ‘Prime Time’

This Biotech Stock With A 221% Gain In 2019 Is Ready For ‘Prime Time’

Arrowhead Pharmaceuticals (ARWR) is using a technology called RNAi to tackle two colossal hurdles in treating genetic diseases. And it’s helping Arrowhead stock to finally realize profits after the biotech company operated for years in the red. RNAi, or RNA interference, is a method of silencing genes. Some genetic diseases cause the overproduction of troublesome proteins.

By | 2019-11-04T10:43:20-04:00 November 1st, 2019|News|Comments Off on This Biotech Stock With A 221% Gain In 2019 Is Ready For ‘Prime Time’

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.